A $74B Market With Two FDA Approvals

A $74B botanical drug market has produced only 2 FDA approvals in history. The bottleneck isn't biology — it's data fragmentation. Traditional medicine knowledge sits in siloed databases: TCM in TCMSP, Ayurveda in IMPPAT, Western herbalism scattered across journals. Researchers stitch together 5–10 disconnected tools to go from plant to drug target.

Meanwhile, AI drug discovery investment has exploded to $2.9B (2025), heading to $13.4B by 2035 — but almost entirely focused on synthetic molecules, leaving natural products underserved.

3IT Phyto sits at the intersection: the first cross-tradition platform that unifies ethnopharmacological data from TCM, Ayurveda, Western herbalism, and African traditional medicine into a single computational pipeline — from plant identification through compound analysis to target discovery and manufacturing readiness.

With 768K compounds, 27K plants, and 24M literature linkages already curated, the dataset itself is a defensible moat. No competitor offers both the cross-tradition data breadth and the end-to-end drug discovery workflow.